When September Ends: A follow up on weathering COVID-19 storm – Vaccines, Biopharma & The Future of Our Economy

Posted -

Zeifmans brings you another exclusive COVID-19 webinar with economist Dr. Peter Andersen and special guest, Dr. Armand Balboni of Bloom Burton & Co. Over the course of their presentation, Peter and Armand address the following topics:

  • Vaccines, biotech and big pharma’s influence on our global economy;
  • Risk and crisis management for your business and beyond;
  • Will we being seeing an end to the pandemic soon;
  • The big (and little) surprises that have come out of the COVID-19;
  • And much, much more.

Listen to the full webinar below:

For more information, contact Zeifmans Partner, Jason Price at jrp@zeifmans.ca or 416.256.4000.

About Dr. Peter Andersen:

Dr. Andersen is an independent consulting economist. He obtained his Ph.D. in economics from Harvard University.

He then worked at Canada’s version of the US Federal Reserve – the Bank of Canada. He became Assistant Chief of its Research
Department, specializing in economic forecasting.

Peter then joined the management consulting firm Woods Gordon, which later became Ernst & Young. He was a partner with this national management consulting firm and he directed its business conditions forecasting practice.

Communication and the need to put economic analysis into terms that are useful for business decision-making are his top priority.

His clients cover a wide range of major corporations, financial institutions and buying groups in sectors such as investment management, portfolio management, insurance, financial planning, human resources, home building, building materials, retailing and trucking.

He communicates with CEOs, company owners and senior management on an on-going basis with boardroom meetings, video conferencing, economic reports, email commentary, conference calls and web based video links.

Disclaimer: The strategies, advice and technical content in this publication are provided for general information only. This publication is not intended to provide specific financial, tax, accounting or other advice for you, and should not be relied upon in that regard. Readers should consult with their professional advisor when planning to implement a strategy to ensure that individual circumstances have been considered properly and it is based on the latest available information.

About Dr. Armand Balboni: 

Dr. Balboni is a partner, senior advisor and member of the Board of Directors of Bloom Burton & Co.

Armand acts as Bloom Burton’s senior most advisor on scientific, regulatory and medical affairs for our incubated companies and clients. He recently completed a period of active duty in the U.S. Army as the Deputy Director, Office of Regulated Activities (ORA) and senior reviewer on their clinical pharmacovigilance team. ORA and its 80-person team provide clinical and regulatory oversight and advisement for more than 100 FDA clinical trials and all associated regulatory filings and meeting necessary for approval. Special emphasis was placed on regulatory filings (EUAs, meetings, pre-sub filings etc.) for military relevant products across all therapeutic areas including vaccines, devices, biologics, and small molecule drugs.

Dr. Balboni completed a DoD fellowship at the U.S. FDA, CDER, Division of Anti-infective Products, and in the Office of the Commissioner and the Office of Counterterrorism and Emerging Threats (OCET). He also served as the Chief, Office of Research and Technology Application (ORTA) at the US Army Research Institute of Infectious Disease (USAMRIID). His office was tasked with oversight of all strategic partnerships between USAMRIID and universities, US and foreign government agencies, and biotechnology and pharmaceutical companies.

Dr. Balboni has held various academic teaching positions including at Westfield State University, the University of Maryland University college, and the United States Military Academy at West Point. He completed his graduate doctoral work at the Icahn School of Medicine at Mount Sinai and his law degree at Brooklyn Law School.

Supplementation Insights

59 Days Later: A follow up COVID-19 discussion with Dr. Peter Andersen

Andersen’s Economic Update in these Uncharted Waters